163 results on '"Kanekiyo M"'
Search Results
2. CRYSTAL STRUCTURE OF HUMAN ANTIBODY 769A9 IN COMPLEX WITH EPSTEIN-BARR VIRUS MAJOR GLYCOPROTEIN GP350
3. Crystal structure of human complement receptor 2 (CD21) in complex with Epstein-Barr virus major glycoprotein gp350
4. Structure of human NDS.1 Fab and 1G01 Fab in complex with influenza virus neuraminidase from A/Indiana/10/2011 (H3N2v), based on consensus cryo-EM map with only Fab 1G01 resolved
5. Structure of human NDS.1 Fab and 1G01 Fab in complex with influenza virus neuraminidase from A/Indiana/10/2011 (H3N2v)
6. Structure of human NDS.3 Fab in complex with influenza virus neuraminidase from A/Darwin/09/2021 (H3N2)
7. Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program
8. Crystal structure of Epstein-Barr virus glycoprotein gH/gL/gp42-peptide in complex with human neutralizing antibodies 769B10 and 769C2
9. Crystal structure of Epstein-Barr virus gH/gL targeting antibody 769B10
10. Virus-Like Particle and Nanoparticle Vaccines
11. List of Contributors
12. Intradermal Delivery of Recombinant Vaccinia Virus Vector DIs Induces Gut-Mucosal Immunity
13. Virus-Like Particle and Nanoparticle Vaccines
14. Mucosal Administration of Completely Non-Replicative Vaccinia Virus Recombinant Dairen I strain Elicits Effective Mucosal and Systemic Immunity
15. NMR Spectroscopy in Polymer Science
16. Contributors
17. Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
18. Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
19. A structural study of (ethylene–vinyl alcohol) copolymers by high-resolution solid-state 13C NMR
20. A structural study of water in a poly(vinyl alcohol) gel by 17O NMR spectroscopy
21. Crystal structure of vaccine-elicited pan- influenza H1N1 neutralizing murine antibody 441D6.
22. Crystal structure of mouse sulfotransferase SULT7A1 complexed with PAP
23. 76P - Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
24. 59PD - Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
25. yeast pyruvyltransferase Pvg1p
26. ChemInform Abstract: NMR Spectroscopy in Polymer Science
27. Cellular zinc status regulates cytomegalovirus major immediate-early promoter
28. Chapter 4 - NMR Spectroscopy in Polymer Science
29. Structural and Dynamic Study of Ethylene−Vinyl Alcohol Copolymer Gels by <SUP>1</SUP>H Pulse NMR and Solid-State <SUP>13</SUP>C NMR
30. A structural and dynamic study of poly(vinyl alcohol) in the gel state by solid-state ^1^3C NMR and ^1H pulse NMR
31. Lecanemab in Early Alzheimer's Disease.
32. ChemInform Abstract: NMR Spectroscopy in Polymer Science.
33. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
34. Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.
35. Antibody sequence determinants of viral antigen specificity.
36. Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
37. Anti-idiotype isolation of a broad and potent influenza A virus-neutralizing human antibody.
38. Immune memory shapes human polyclonal antibody responses to H2N2 vaccination.
39. Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses.
40. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
41. Enterovirus virus-like-particle and inactivated poliovirus vaccines do not elicit substantive cross-reactive antibody responses.
42. C1q enables influenza hemagglutinin stem binding antibodies to block viral attachment and broadens the antibody escape repertoire.
43. Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase.
44. A new type of sulfation reaction: C -sulfonation for α,β-unsaturated carbonyl groups by a novel sulfotransferase SULT7A1.
45. Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.
46. Antigen spacing on protein nanoparticles influences antibody responses to vaccination.
47. Combinatorial immune refocusing within the influenza hemagglutinin RBD improves cross-neutralizing antibody responses.
48. Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera.
49. Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus.
50. Refined semi-lethal aerosol H5N1 influenza model in cynomolgus macaques for evaluation of medical countermeasures.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.